Cargando…
Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson’s disease
Aging, genetics and environmental toxicity are important etiological factors in Parkinson’s disease (PD). However, its pathogenesis remains unclear. A major obstacle is the lack of an appropriate experimental model which incorporates genetic susceptibility, aging and prolonged environmental toxicity...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241661/ https://www.ncbi.nlm.nih.gov/pubmed/28098219 http://dx.doi.org/10.1038/srep40887 |
_version_ | 1782496222819385344 |
---|---|
author | Liu, Hui-Fang Ho, Philip Wing-Lok Leung, Gideon Chi-Ting Lam, Colin Siu-Chi Pang, Shirley Yin-Yu Li, Lingfei Kung, Michelle Hiu-Wai Ramsden, David Boyer Ho, Shu-Leong |
author_facet | Liu, Hui-Fang Ho, Philip Wing-Lok Leung, Gideon Chi-Ting Lam, Colin Siu-Chi Pang, Shirley Yin-Yu Li, Lingfei Kung, Michelle Hiu-Wai Ramsden, David Boyer Ho, Shu-Leong |
author_sort | Liu, Hui-Fang |
collection | PubMed |
description | Aging, genetics and environmental toxicity are important etiological factors in Parkinson’s disease (PD). However, its pathogenesis remains unclear. A major obstacle is the lack of an appropriate experimental model which incorporates genetic susceptibility, aging and prolonged environmental toxicity. Here, we explored the interplay amongst these factors using mutant LRRK2(R1441G) (leucine-rich-repeat-kinase-2) knockin mice. We found that mutant primary cortical and mesencephalic dopaminergic neurons were more susceptible to rotenone-induced ATP deficiency and cell death. Compared with wild-type controls, striatal synaptosomes isolated from young mutant mice exhibited significantly lower dopamine uptake after rotenone toxicity, due to reduced striatal synaptosomal mitochondria and synaptic vesicular proton pump protein (V-ATPase H) levels. Mutant mice developed greater locomotor deficits in open-field tests than wild-type mice following low oral rotenone doses given twice weekly over 50 weeks (half their lifespan). The increased locomotor deficit was associated with specific reduction in striatal mitochondrial Complex-I (NDUFS4) in rotenone-treated mutant but not in similarly treated wild-type mice. Our unique experimental model which incorporates genetic effect, natural aging and prolonged oral environmental toxicity administered to mutant knockin LRRK2 mice over half their life span, with observable and measurable phenotype, is invaluable in further studies of the pathogenic process and therapeutics of PD. |
format | Online Article Text |
id | pubmed-5241661 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-52416612017-01-23 Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson’s disease Liu, Hui-Fang Ho, Philip Wing-Lok Leung, Gideon Chi-Ting Lam, Colin Siu-Chi Pang, Shirley Yin-Yu Li, Lingfei Kung, Michelle Hiu-Wai Ramsden, David Boyer Ho, Shu-Leong Sci Rep Article Aging, genetics and environmental toxicity are important etiological factors in Parkinson’s disease (PD). However, its pathogenesis remains unclear. A major obstacle is the lack of an appropriate experimental model which incorporates genetic susceptibility, aging and prolonged environmental toxicity. Here, we explored the interplay amongst these factors using mutant LRRK2(R1441G) (leucine-rich-repeat-kinase-2) knockin mice. We found that mutant primary cortical and mesencephalic dopaminergic neurons were more susceptible to rotenone-induced ATP deficiency and cell death. Compared with wild-type controls, striatal synaptosomes isolated from young mutant mice exhibited significantly lower dopamine uptake after rotenone toxicity, due to reduced striatal synaptosomal mitochondria and synaptic vesicular proton pump protein (V-ATPase H) levels. Mutant mice developed greater locomotor deficits in open-field tests than wild-type mice following low oral rotenone doses given twice weekly over 50 weeks (half their lifespan). The increased locomotor deficit was associated with specific reduction in striatal mitochondrial Complex-I (NDUFS4) in rotenone-treated mutant but not in similarly treated wild-type mice. Our unique experimental model which incorporates genetic effect, natural aging and prolonged oral environmental toxicity administered to mutant knockin LRRK2 mice over half their life span, with observable and measurable phenotype, is invaluable in further studies of the pathogenic process and therapeutics of PD. Nature Publishing Group 2017-01-18 /pmc/articles/PMC5241661/ /pubmed/28098219 http://dx.doi.org/10.1038/srep40887 Text en Copyright © 2017, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Liu, Hui-Fang Ho, Philip Wing-Lok Leung, Gideon Chi-Ting Lam, Colin Siu-Chi Pang, Shirley Yin-Yu Li, Lingfei Kung, Michelle Hiu-Wai Ramsden, David Boyer Ho, Shu-Leong Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson’s disease |
title | Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson’s disease |
title_full | Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson’s disease |
title_fullStr | Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson’s disease |
title_full_unstemmed | Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson’s disease |
title_short | Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson’s disease |
title_sort | combined lrrk2 mutation, aging and chronic low dose oral rotenone as a model of parkinson’s disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241661/ https://www.ncbi.nlm.nih.gov/pubmed/28098219 http://dx.doi.org/10.1038/srep40887 |
work_keys_str_mv | AT liuhuifang combinedlrrk2mutationagingandchroniclowdoseoralrotenoneasamodelofparkinsonsdisease AT hophilipwinglok combinedlrrk2mutationagingandchroniclowdoseoralrotenoneasamodelofparkinsonsdisease AT leunggideonchiting combinedlrrk2mutationagingandchroniclowdoseoralrotenoneasamodelofparkinsonsdisease AT lamcolinsiuchi combinedlrrk2mutationagingandchroniclowdoseoralrotenoneasamodelofparkinsonsdisease AT pangshirleyyinyu combinedlrrk2mutationagingandchroniclowdoseoralrotenoneasamodelofparkinsonsdisease AT lilingfei combinedlrrk2mutationagingandchroniclowdoseoralrotenoneasamodelofparkinsonsdisease AT kungmichellehiuwai combinedlrrk2mutationagingandchroniclowdoseoralrotenoneasamodelofparkinsonsdisease AT ramsdendavidboyer combinedlrrk2mutationagingandchroniclowdoseoralrotenoneasamodelofparkinsonsdisease AT hoshuleong combinedlrrk2mutationagingandchroniclowdoseoralrotenoneasamodelofparkinsonsdisease |